It’s a matter of time for Cyprus to obtain monoclonal antibody medicines for COVID, deputy head of pharmaceutical providers Elena Panagiotopoulou advised Cyprus Information Company on Thursday.
She stated that the division of purchases and provides of the Well being Ministry is in contact with the manufacturing firm.
EMA’s human medicines committee (CHMP) has really helpful authorising Ronapreve (casirivimab/imdevimab) and Regkirona (regdanvimab) for COVID-19.
The Committee really helpful authorising Ronapreve for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at the very least 40 kilograms) who don’t require supplemental oxygen and who’re at elevated danger of their illness turning into extreme.
Ronapreve will also be used for stopping COVID-19 in individuals aged 12 years and older weighing at the very least 40 kilograms. The corporate that utilized for authorisation of Ronapreve was Roche Registration GmbH.
With regard to Regkirona, the Committee really helpful authorising the medication for treating adults with COVID-19 who don’t require supplemental oxygen and who’re additionally at elevated danger of their illness turning into extreme. The applicant for Regkirona was Celltrion Healthcare Hungary Kft.
Dr. Panagiotopoulou advised CNA that the manufacturing firm couldn’t say precisely when the provides of those medicines will attain EU member states, however clarified that when the remainder of the international locations are handed these new medicine, Cyprus will receive them too. The manufacturing firm began the manufacturing of those medicines on November 12 when it obtained the inexperienced gentle for authorization.
Cyprus will obtain provides in keeping with its inhabitants, Dr. Panagiotopoulou added.
She stated that these medicines will likely be administered to sufferers on the premise of a protocol. Solely hospital sufferers will likely be given these medicine.
She clarified that monoclonal antibody medicines aren’t administered to the final inhabitants and the recommendation is for them to be administered to sufferers with delicate or average sickness and earlier than the affected person is placed on oxygen remedy, in order that the heavy sickness and dying don’t happen. However she famous that this sort of therapies might not at all substitute the inoculations.
Deputy head of the pharmaceutical providers additionally stated that there’s a lot of developments on new therapies for COVID and vaccines and added that when there’s an authorisation and provide, Cyprus will obtain them too.
She assured that Cyprus is within the provide course of the identical as different member states.
Cyprus can also be taking part within the procedures for Pfizer’s antiviral capsule, which in keeping with the manufacturing firm decreases the possibilities of hospitalisation or dying in grownup inhabitants who’re susceptible to critical sickness by 89%.
Dr. Panagiotopoulou additionally stated that to start with of subsequent yr the brand new capsule molnupiravir, also called MK4482 or Lagevrio is ready to get authorisation for COVID remedy in adults. The capsule is produced by Merck Sharp & Dohme in cooperation with Ridgeback Biotherapeutics.